Journal of Gerontological Nursing

Product News Free

Product News

New iStand Walking Cane With SmartWalk Technology™ Aids Joint Relief in Older Adults With Alzheimer's Disease

WhatBox, Inc., announced its newest product, the iStand Walking Cane with SmartWalk Technology™. The iStand Walking Cane features a unique, scientific design to optimize comfort and aid in joint relief, and is equipped with Fall Detection Alerts, Global Positioning System location, and Alzheimer'sAlert's™.

The iStand Walking Cane is designed with older adult falls and Alzheimer's disease in mind. Loved ones will receive a fall alert with the SmartWalk user's location; neighbors on NextDoor.com and Facebook® will receive alerts when the user has wandered away from his/her designated radius. In addition to the cane's unique design aiding joint relief, it is equipped with optional features such as a 911 Panic Button, data collection, and a QR code fingernail sticker that contains users' contact information in case they become lost or disoriented.

Source.“New iStand Walking Cane With SmartWalk™ Technology to Revolutionize Healthcare for Senior Citizens and Those With Alzheimer's and Dementia.” (2017, February 22). Retrieved February 23, 2017, from http://prn.to/2lJ5lOQ.

Phase 2 Trials Begin for ABBV-8E12 for Patients With Alzheimer's Disease and Progressive Supranuclear Palsy

AbbVie announced the start of two Phase 2 clinical trial programs to evaluate ABBV-8E12, an investigational anti-tau antibody, in patients with early Alzheimer's disease and progressive supranuclear palsy (PSP). In recognition of the lack of treatment options available to patients with PSP, the U.S. Food and Drug Administration granted Fast Track Designation to ABBV-8E12.

The Phase 2 clinical trial programs follow completion of pre-clinical studies and a Phase 1 study in patients with PSP, which supported the further development of ABBV-8E12 in PSP and early Alzheimer's disease. The Phase 2 study in early Alzheimer's disease will enroll 400 patients to assess the efficacy and safety of ABBV-8E12 to delay disease progression. The Phase 2 study in PSP will evaluate 180 adults and assess the efficacy and safety of ABBV-8E12 to slow disease progression.

Source.“AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy.” (2017, January 25). Retrieved February 23, 2017, from http://prn.to/2moMHJ7.

Authors

10.3928/00989134-20170313-02

Sign up to receive

Journal E-contents